Evidence map›Paper›PMID 39902071›Full record

ArticleFrontiers in pharmacology2024

4,6-Disubstituted pyrimidine-based microtubule affinity-regulating kinase 4 (MARK4) inhibitors: synthesis, characterization,

Ashanul Haque, Khalaf M Alenezi, Mohd Saeed Maulana Abdul Rasheed, Md Ataur Rahman, Saleha Anwar, Shahzaib Ahamad, Dinesh Gupta

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ashanul HaqueDepartment of Chemistry, College of Science, University of Hail, Ha'il, Saudi Arabia.
Khalaf M AleneziDepartment of Chemistry, College of Science, University of Hail, Ha'il, Saudi Arabia.
Mohd Saeed Maulana Abdul RasheedDepartment of Biology, College of Science, University of Hail, Ha'il, Saudi Arabia.
Md Ataur RahmanChemistry Program, New York University Abu Dhabi (NYUAD), Abu Dhabi, United Arab Emirates.
Saleha AnwarCentre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi, India.
Shahzaib AhamadTranslational Bioinformatics Group, International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India.
Dinesh GuptaTranslational Bioinformatics Group, International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Alzheimer's disease (AD) is a neurodegenerative disorder that significantly impacts the cognitive function and memory of a person. Despite the significant research efforts, the ability to completely prevent or effectively treat AD and its related dementias remains limited. Protein kinases are integral to AD pathology and represent promising targets for therapeutic intervention. Methods: A series of pyrimidine-based compounds 4-(4-(arylsulfonyl)piperazin-1-yl)-6-(thiophen-3-yl)pyrimidine derivatives ( Results: Compounds were synthesized following a multi-step approach and characterized using multi-nuclear magnetic resonance ( Conclusion: Using experimental and theoretical approaches, we demonstrated that the reported class of pyrimidine derivatives are an excellent starting point for developing the next-generation anti-AD drugs.

Indexed as

Alzheimer’s diseasekinase inhibitorsmark 4pyrimidinesynthesis

Identifiers

PMID39902071
PMCPMC11788324

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.